FULC - Fulcrum climbs as FDA lifts clinical hold on sickle-cell disease candidate
2023-08-22 08:09:03 ET
More on Fulcrum
- Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD
- Fulcrum inks licensing deal for rare blood disorder
- Fulcrum slips as Goldman Sachs downgrades on limited catalyst path
- Fulcrum Therapeutics downgraded to neutral at Credit Suisse on sickle cell candidate
- Seeking Alpha’s Quant Rating on Fulcrum Therapeutics
- Earnings data for Fulcrum Therapeutics
For further details see:
Fulcrum climbs as FDA lifts clinical hold on sickle-cell disease candidate